journal article·2020-09Open access

Low dose novel PARP-PI3K inhibition via nanoformulation improves colorectal cancer immunoradiotherapy

M.R. Landry, A.N. DuRoss, M.J. Neufeld, L. Hahn, G. Sahay, R. Luxenhofer, C. Sun

Abstract

Multimodal therapy is often used in oncology to overcome dosing limitations and chemoresistance. Recently, combination immunoradiotherapy has shown great promise in a select subset of patients with colorectal cancer (CRC). Furthermore, molecularly targeted agents delivered in tandem with immunotherapy regimens have been suggested to improve treatment outcomes and expand the population of responding patients. In this study, radiation-sensitizing small molecules niraparib (PARP inhibitor) and HS-173 (PI3K inhibitor) are identified as a novel combination that synergistically enhance toxicity and induce immunogenic cell death both in vitro and in vivo in a CRC model. These inhibitors were co-encapsulated in a polymer micelle to overcome solubility limitations while minimizing off-target toxicity. Mice bearing syngeneic colorectal tumors (CT26) were administered these therapeutic micelles in combination with X-ray irradiation and anti-CTLA-4 immunotherapy. This combination led to enhanced efficacy demonstrated by improved tumor control and increased tumor infiltrating lymphocytes. This report represents the first investigation of DNA damage repair inhibition combined with radiation to potentiate anti-CTLA-4 immunotherapy in a CRC model.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: PARP inhibition in cancer therapy · Cancer Immunotherapy and Biomarkers · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (63)

Show source-provided references
1. 2019
2. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed10.1038/bjc.2017.376 ↗
3. Overman · 2018 · 239
4. Advances in immunotherapy in the treatment of colorectal cancer
5. Updates on immunotherapy for colorectal cancer10.21037/jgo.2018.01.17 ↗
6. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer10.1200/JCO.2017.76.9901 ↗
7. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis10.1186/s12916-015-0455-8 ↗
8. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer10.1158/2159-8290.CD-18-1020 ↗
9. Exploiting DNA repair defects in colorectal cancer10.1002/1878-0261.12467 ↗
10. Prospects for combining immune checkpoint blockade with PARP inhibition10.1186/s13045-019-0784-8 ↗
11. PARP inhibitor efficacy depends on CD8 + T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer10.1158/2159-8290.CD-18-1218 ↗
12. PI3K p110α inhibition sensitizes cervical cancer cells with aberrant PI3K signaling activation to PARP inhibitor BMN673
13. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition10.1158/2159-8290.CD-11-0348 ↗
14. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer10.1158/2159-8290.CD-11-0336 ↗
15. Micellar formulation of talazoparib and buparlisib for enhanced DNA damage in breast cancer chemoradiotherapy10.1021/acsami.9b02408 ↗
16. Co-delivery of PARP and PI3K inhibitors by nanoscale metal–organic frameworks for enhanced tumor chemoradiation10.1007/s12274-019-2544-z ↗
17. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer10.1186/s12885-015-1090-7 ↗
18. HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis10.1016/j.canlet.2012.08.020 ↗
19. Novel formulations of taxanes: a review. Old wine in a new bottle?10.1093/annonc/mdj100 ↗
20. Drug delivery systems based on poly(2-oxazoline)s and poly(2-oxazine)s10.1002/adtp.201900168 ↗
21. Poly(2-oxazoline)s based biomaterials: a comprehensive and critical update10.1016/j.biomaterials.2018.05.022 ↗
22. Think beyond the core: the impact of the hydrophilic corona on the drug solubilization using polymer micelles10.1021/acsami.9b22495 ↗
23. A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin10.1158/1078-0432.CCR-19-2409 ↗
24. ATM-deficient colorectal cancer cells are sensitive to the PARP inhibitor olaparib10.1016/j.tranon.2017.01.007 ↗
25. Portrait of the PI3K/AKT pathway in colorectal cancer10.1016/j.bbcan.2014.09.008 ↗
26. Association of phosphatidylinositol 3-kinase (PI3K) pathway activation with increased immune checkpoint expression in colorectal cancer (CRC) patients
27. Drug combination studies and their synergy quantification using the chou-talalay method10.1158/0008-5472.CAN-09-1947 ↗
28. HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer10.18632/oncotarget.12871 ↗
29. HS-173 as a novel inducer of RIP3-dependent necroptosis in lung cancer10.1016/j.canlet.2018.12.006 ↗
30. Combinatorial strategies for the induction of immunogenic cell death
31. Immunogenic effects of chemotherapy-induced tumor cell death10.1016/j.gendis.2018.05.003 ↗
32. Immunogenic death of colon cancer cells treated with oxaliplatin10.1038/onc.2009.356 ↗
33. Calreticulin exposure dictates the immunogenicity of cancer cell death10.1038/nm1523 ↗
34. Combining PARP inhibition, radiation, and immunotherapy: a possible strategy to improve the treatment of cancer?10.3390/ijms19123793 ↗
35. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models10.1038/s41598-019-38534-6 ↗
36. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy10.1016/j.immuni.2015.11.024 ↗
37. Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors10.1038/s41467-019-09221-x ↗
38. Role of oxaliplatin in the treatment of colorectal cancer10.2147/TCRM.S3583 ↗
39. Immunogenic cell death and immunotherapy of multiple myeloma
40. The oncolytic peptide LTX-315 triggers immunogenic cell death10.1038/cddis.2016.47 ↗
41. Synergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micelles10.1021/mp300159u ↗
42. Overcoming the PEG-addiction: well-defined alternatives to PEG, from structure–property relationships to better defined therapeutics10.1039/c0py00406e ↗
43. POxylation as an alternative stealth coating for biomedical applications10.1016/j.eurpolymj.2016.10.041 ↗
44. Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson's disease – proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications10.1016/j.eurpolymj.2016.09.052 ↗
45. Investigating the influence of aromatic moieties on the formulation of hydrophobic natural products and drugs in poly(2-oxazoline)-based amphiphiles10.1021/acs.biomac.8b00708 ↗
46. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size10.1038/nnano.2011.166 ↗
47. Drug induced micellization into ultra-high capacity and stable curcumin nanoformulations: physico-chemical characterization and evaluation in 2D and 3D in vitro models10.1016/j.jconrel.2019.04.014 ↗
48. Drug-induced morphology switch in drug delivery systems based on poly(2-oxazoline)s10.1021/nn406388t ↗
49. Like dissolves like? A comprehensive evaluation of partial solubility parameters to predict polymer–drug compatibility in ultrahigh drug-loaded polymer micelles10.1021/acs.biomac.9b00618 ↗
50. Niraparib in ovarian cancer: results to date and clinical potential10.1177/1758834017718775 ↗
51. Conversion of DNA damage into chromosome damage in response to cell cycle regulation of chromatin condensation after irradiation10.1093/mutage/12.4.271 ↗
52. Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer10.18632/oncotarget.22850 ↗
53. Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay10.1371/journal.pone.0171582 ↗
54. Structure-property relationship in cytotoxicity and cell uptake of poly(2-oxazoline) amphiphiles10.1016/j.jconrel.2011.04.010 ↗
55. Drug combination synergy in worm-like polymeric micelles improves treatment outcome for small cell and non-small cell lung cancer10.1021/acsnano.7b07878 ↗
56. Co-delivery of paclitaxel and cisplatin in poly(2-oxazoline) polymeric micelles: implications for drug loading, release, pharmacokinetics and outcome of ovarian and breast cancer treatments10.1016/j.biomaterials.2018.10.032 ↗
57. A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs10.1021/mp2000549 ↗
58. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells10.1016/j.canlet.2013.01.007 ↗
59. Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy10.1371/journal.pone.0157164 ↗
60. A review on nano-based drug delivery system for cancer chemoimmunotherapy10.1007/s40820-020-00482-6 ↗
61. Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo10.4049/jimmunol.164.5.2619 ↗
62. Cytoplasmic vacuolization during exposure to drugs and other substances10.1007/s10565-012-9212-3 ↗
63. PARP inhibition prevents acetaminophen-induced liver injury and increases survival rate in rats10.3906/sag-1308-48 ↗